

# Marco Ruggeri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7926530/publications.pdf>

Version: 2024-02-01

15  
papers

2,653  
citations

758635

12  
h-index

1058022

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

2743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009, 113, 2386-2393.	0.6	2,128
2	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013, 121, 2596-2606.	0.6	179
3	The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis. <i>Annals of Internal Medicine</i> , 2003, 139, 470.	2.0	65
4	Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use. <i>Stem Cell Research and Therapy</i> , 2017, 8, 14.	2.4	49
5	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. <i>American Journal of Hematology</i> , 2018, 93, 751-759.	2.0	38
6	High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources. <i>Stem Cell Research and Therapy</i> , 2018, 9, 10.	2.4	37
7	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31
8	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018, 93, 58-64.	2.0	31
9	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	0.6	26
10	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. <i>European Journal of Haematology</i> , 2020, 105, 468-475.	1.1	21
11	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	1.3	16
12	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.4	13
13	Thrombotic and hemorrhagic complications in idiopathic erythrocytosis. <i>American Journal of Hematology</i> , 2017, 92, E639-E641.	2.0	11
14	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
15	A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. <i>Heliyon</i> , 2021, 7, e06036.	1.4	0